BAX and pulmonary fibrosis: Some researchers have targeted BAX to develop short peptide inhibitors, which significantly improve the progression of type I diabetes [184] or pulmonary fibrosis [185], but research on BAX/BAK inhibitors for IR has not yet been conducted.